Higher PME-1 expression is observed in various cancer types and is associated with a worse prognosis of gliomas, liver cancer, and prostate cancer (12, 13, 14), indicating that dysfunction of PP2A holoenzyme due to elevated PME-1 contributes to cancer development and malignant transformation. Here, PPME1 is linked to prostate cancer.